Article
Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.
Blood - 2 Jan 2020
Li Benshang, Brady Samuel W, Ma Xiaotu, Shen Shuhong, Zhang Yingchi, Li Yongjin, Szlachta Karol, Dong Li, Liu Yu, Yang Fan, Wang Ningling, Flasch Diane A, Myers Matthew A, Mulder Heather L, Ding Lixia, Liu Yanling, Tian Liqing, Hagiwara Kohei, Xu Ke, Zhou Xin, Sioson Edgar, Wang Tianyi, Yang Liu, Zhao Jie, Zhang Hui, Shao Ying, Sun Hongye, Sun Lele, Cai Jiaoyang, Sun Hui-Ying, Lin Ting-Nien, Du Lijuan, Li Hui, Rusch Michael, Edmonson Michael N, Easton John, Zhu Xiaofan, Zhang Jingliao, Cheng Cheng, Raphael Benjamin J, Tang Jingyan, Downing James R, Alexandrov Ludmil B, Zhou Bin-Bing S, Pui Ching-Hon, Yang Jun J, Zhang Jinghui
Abstract excerpt
To study the mechanisms of relapse in acute lymphoblastic leukemia (ALL), we performed whole-genome sequencing of 103 diagnosis-relapse-germline trios and ultra-deep sequencing of 208 serial samples in 16 patients. Relapse-specific somatic alterations were enriched in 12 genes (NR3C1, NR3C2, TP53, NT5C2, FPGS, CREBBP, MSH2, MSH6, PMS2, WHSC1, PRPS1, and PRPS2) involved in drug response. Their prevalence was 17%...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.